anti-CD47 nanobody

An anti-CD47 nanobody is a single-domain antibody fragment (VHH) derived from camelid heavy-chain-only antibodies designed to target CD47, an integrin-associated protein overexpressed on many cancer cells that acts as a 'don't eat me' signal. By binding to CD47, these nanobodies block its interaction with signal-regulatory protein alpha (SIRPα) on macrophages, thereby promoting macrophage-mediated phagocytosis of tumor cells. Due to their small size (~12-15 kDa), nanobodies offer advantages such as deeper tumor penetration and lower production costs compared to conventional monoclonal antibodies. Furthermore, many anti-CD47 nanobodies are engineered to have low affinity for red blood cells, significantly reducing the risk of hemagglutination and anemia, which are common dose-limiting toxicities of traditional anti-CD47 monoclonal antibodies.

Other names

CD47 nanobodyCD-47 nanobodyCD 47 nanobodyanti-CD47 VHHanti-CD-47 VHHanti-CD 47 VHHanti-CD47 single-domain antibodyanti-CD-47 single-domain antibodyanti-CD 47 single-domain antibody